Table 2.
Peptides from SARS-CoV-2 predicted to bind to multiple HLA-DR molecules included in the second vaccination (3 April 2020).
| AA Sequence | Source Protein | Peptide ID | AA Position | Peptide Length |
|---|---|---|---|---|
| ASVYAWNRKRISN | SARS-CoV-2 spike | spi-DR-1 | 348–360 | 13 |
| VADYSVLYNSASFST | spi-DR-2 | 362–376 | 15 | |
| IGYYRRATRRIRGGD | SARS-CoV-2 nuc | nuc-DR-1 | 84–98 | 15 |
| ASAFFGMSRIGMEVT | nuc-DR-2 | 311–325 | 15 | |
| RWYFYYLGTGPEAGL | nuc-DR-5 | 107–121 | 15 | |
| ASWFTALTQHGKEDL | nuc-DR-6 | 50–64 | 15 | |
| LLLLDRLNQLESKMS | nuc-DR-7 | 221–235 | 15 | |
| AADLDDFSKQLQQSM | nuc-DR-8 | 397–411 | 15 | |
| AIVLQLPQGTTLPKG | nuc-DR-9 | 156–170 | 15 | |
| YKHWPQIAQFAPSAS | nuc-DR-10 | 298–312 | 15 |
Vaccination was performed with synthetic peptides solubilized in water and 20% DMSO including 50 μg XS15 as an adjuvant, emulsified in Montanide ISA51 VG in a total volume of 0.5 mL. Peptides already used in the first vaccination (6 March 2020) (boost) are shown in italics. The peptide amount administered in the vaccine was 240 μg for each peptide. Abbreviations: AA—amino acid, DMSO—dimethyl sulfoxide, HLA—human leukocyte antigen, and nuc—nucleoprotein.